| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Telemedicine | 14 | 2024 | 184 | 7.390 |
Why?
|
| Emergency Service, Hospital | 45 | 2024 | 382 | 5.430 |
Why?
|
| Electronic Health Records | 19 | 2024 | 747 | 3.380 |
Why?
|
| Patient Acceptance of Health Care | 10 | 2024 | 407 | 2.750 |
Why?
|
| Pulmonary Embolism | 12 | 2023 | 44 | 2.530 |
Why?
|
| Humans | 104 | 2024 | 18430 | 2.510 |
Why?
|
| Primary Health Care | 11 | 2024 | 848 | 2.430 |
Why?
|
| Male | 77 | 2024 | 10440 | 2.360 |
Why?
|
| Office Visits | 6 | 2024 | 86 | 2.350 |
Why?
|
| Female | 78 | 2024 | 13136 | 2.120 |
Why?
|
| Patient Portals | 4 | 2020 | 25 | 2.100 |
Why?
|
| Health Expenditures | 4 | 2017 | 82 | 2.100 |
Why?
|
| Anticoagulants | 8 | 2024 | 125 | 2.050 |
Why?
|
| Adult | 54 | 2024 | 7910 | 2.050 |
Why?
|
| Diabetes Mellitus | 6 | 2020 | 530 | 2.030 |
Why?
|
| Decision Support Systems, Clinical | 8 | 2024 | 56 | 2.010 |
Why?
|
| Middle Aged | 56 | 2024 | 8284 | 1.940 |
Why?
|
| Delivery of Health Care, Integrated | 12 | 2021 | 567 | 1.930 |
Why?
|
| Aged | 47 | 2024 | 6417 | 1.790 |
Why?
|
| Electronic Mail | 5 | 2021 | 53 | 1.750 |
Why?
|
| Retrospective Studies | 33 | 2024 | 2550 | 1.740 |
Why?
|
| Videoconferencing | 4 | 2021 | 7 | 1.670 |
Why?
|
| Pandemics | 7 | 2024 | 292 | 1.490 |
Why?
|
| Patient Satisfaction | 5 | 2019 | 232 | 1.480 |
Why?
|
| Cost Sharing | 6 | 2017 | 40 | 1.480 |
Why?
|
| Medication Adherence | 3 | 2020 | 267 | 1.480 |
Why?
|
| Ambulatory Care | 5 | 2022 | 266 | 1.470 |
Why?
|
| California | 28 | 2024 | 2365 | 1.460 |
Why?
|
| Atrial Fibrillation | 6 | 2024 | 167 | 1.450 |
Why?
|
| Deductibles and Coinsurance | 5 | 2017 | 31 | 1.410 |
Why?
|
| Telephone | 7 | 2024 | 179 | 1.310 |
Why?
|
| Chronic Disease | 4 | 2019 | 468 | 1.310 |
Why?
|
| Internet | 4 | 2020 | 243 | 1.230 |
Why?
|
| Physicians | 4 | 2023 | 141 | 1.160 |
Why?
|
| Health Benefit Plans, Employee | 5 | 2017 | 20 | 1.140 |
Why?
|
| Choice Behavior | 2 | 2020 | 48 | 1.120 |
Why?
|
| Heart Failure | 3 | 2023 | 398 | 1.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 8 | 2014 | 392 | 1.120 |
Why?
|
| Insurance, Health | 5 | 2017 | 217 | 1.120 |
Why?
|
| Health Services Accessibility | 6 | 2020 | 320 | 1.070 |
Why?
|
| Young Adult | 19 | 2021 | 2518 | 1.060 |
Why?
|
| Adolescent | 21 | 2024 | 3798 | 1.050 |
Why?
|
| Consumer Behavior | 2 | 2020 | 30 | 1.040 |
Why?
|
| Physicians, Primary Care | 3 | 2021 | 74 | 1.040 |
Why?
|
| Cross-Sectional Studies | 13 | 2024 | 1360 | 1.000 |
Why?
|
| Craniocerebral Trauma | 5 | 2021 | 10 | 0.960 |
Why?
|
| Language | 1 | 2024 | 52 | 0.940 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2023 | 208 | 0.930 |
Why?
|
| Hospitalization | 9 | 2024 | 847 | 0.930 |
Why?
|
| Risk Assessment | 9 | 2024 | 1143 | 0.880 |
Why?
|
| Musculoskeletal Pain | 1 | 2023 | 28 | 0.880 |
Why?
|
| Financing, Personal | 3 | 2017 | 24 | 0.870 |
Why?
|
| Glycated Hemoglobin A | 3 | 2020 | 233 | 0.850 |
Why?
|
| Specialties, Surgical | 1 | 2022 | 2 | 0.840 |
Why?
|
| Allied Health Personnel | 1 | 2022 | 13 | 0.820 |
Why?
|
| Hypoglycemic Agents | 2 | 2017 | 288 | 0.820 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 211 | 0.810 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 444 | 0.780 |
Why?
|
| Aftercare | 1 | 2021 | 48 | 0.770 |
Why?
|
| Contrast Media | 1 | 2021 | 9 | 0.770 |
Why?
|
| Warfarin | 4 | 2018 | 73 | 0.760 |
Why?
|
| Multitasking Behavior | 1 | 2021 | 2 | 0.760 |
Why?
|
| Attention | 1 | 2021 | 10 | 0.750 |
Why?
|
| United States | 16 | 2024 | 4164 | 0.740 |
Why?
|
| Aged, 80 and over | 17 | 2024 | 2003 | 0.730 |
Why?
|
| Machine Learning | 1 | 2020 | 44 | 0.720 |
Why?
|
| Attitude of Health Personnel | 7 | 2021 | 226 | 0.720 |
Why?
|
| Communication | 3 | 2018 | 202 | 0.720 |
Why?
|
| Caregivers | 2 | 2019 | 126 | 0.710 |
Why?
|
| Stroke | 6 | 2024 | 311 | 0.700 |
Why?
|
| Insurance Coverage | 6 | 2020 | 136 | 0.690 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 241 | 0.670 |
Why?
|
| Opioid-Related Disorders | 1 | 2022 | 168 | 0.670 |
Why?
|
| Income | 5 | 2016 | 98 | 0.670 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 180 | 0.660 |
Why?
|
| Atrial Flutter | 4 | 2023 | 15 | 0.650 |
Why?
|
| Ticlopidine | 3 | 2013 | 16 | 0.640 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2013 | 24 | 0.640 |
Why?
|
| Cohort Studies | 10 | 2024 | 2672 | 0.630 |
Why?
|
| Chest Pain | 3 | 2024 | 14 | 0.600 |
Why?
|
| Patient Discharge | 4 | 2024 | 153 | 0.590 |
Why?
|
| Health Maintenance Organizations | 5 | 2013 | 479 | 0.570 |
Why?
|
| Intracranial Hemorrhages | 3 | 2013 | 16 | 0.560 |
Why?
|
| Computer Security | 1 | 2016 | 8 | 0.560 |
Why?
|
| Access to Information | 1 | 2016 | 13 | 0.550 |
Why?
|
| Efficiency, Organizational | 2 | 2015 | 36 | 0.550 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 44 | 0.540 |
Why?
|
| Motivation | 1 | 2017 | 137 | 0.540 |
Why?
|
| Asthma | 1 | 2019 | 390 | 0.530 |
Why?
|
| Quality of Health Care | 2 | 2015 | 347 | 0.530 |
Why?
|
| Insurance, Pharmaceutical Services | 2 | 2008 | 27 | 0.520 |
Why?
|
| Surveys and Questionnaires | 10 | 2021 | 1389 | 0.510 |
Why?
|
| Patient-Centered Care | 1 | 2018 | 228 | 0.500 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2022 | 350 | 0.500 |
Why?
|
| Patient Participation | 1 | 2016 | 144 | 0.500 |
Why?
|
| Continental Population Groups | 2 | 2016 | 315 | 0.490 |
Why?
|
| Child | 10 | 2024 | 2571 | 0.480 |
Why?
|
| Catheterization, Central Venous | 4 | 2014 | 12 | 0.480 |
Why?
|
| Health Care Costs | 2 | 2012 | 251 | 0.450 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 760 | 0.440 |
Why?
|
| Infant | 5 | 2024 | 1245 | 0.440 |
Why?
|
| Ambulatory Care Facilities | 3 | 2020 | 77 | 0.430 |
Why?
|
| Health Planning | 1 | 2012 | 17 | 0.430 |
Why?
|
| Community Participation | 1 | 2012 | 33 | 0.420 |
Why?
|
| Medical Savings Accounts | 1 | 2012 | 1 | 0.420 |
Why?
|
| Severity of Illness Index | 5 | 2024 | 476 | 0.420 |
Why?
|
| Follow-Up Studies | 5 | 2023 | 1269 | 0.410 |
Why?
|
| Child, Preschool | 5 | 2024 | 1478 | 0.410 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2012 | 254 | 0.400 |
Why?
|
| Patient Compliance | 2 | 2018 | 318 | 0.390 |
Why?
|
| Age Factors | 6 | 2020 | 965 | 0.380 |
Why?
|
| Preventive Health Services | 1 | 2012 | 166 | 0.380 |
Why?
|
| Qualitative Research | 4 | 2022 | 272 | 0.370 |
Why?
|
| Medical Oncology | 2 | 2021 | 32 | 0.370 |
Why?
|
| Appendicitis | 2 | 2020 | 16 | 0.350 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2024 | 4 | 0.340 |
Why?
|
| Interviews as Topic | 5 | 2013 | 327 | 0.340 |
Why?
|
| Physician-Patient Relations | 3 | 2019 | 197 | 0.340 |
Why?
|
| Sepsis | 3 | 2014 | 71 | 0.330 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 598 | 0.330 |
Why?
|
| Predictive Value of Tests | 4 | 2024 | 365 | 0.330 |
Why?
|
| Drug Costs | 2 | 2013 | 40 | 0.320 |
Why?
|
| Patient Care Team | 3 | 2021 | 127 | 0.310 |
Why?
|
| Triage | 2 | 2024 | 17 | 0.300 |
Why?
|
| Managed Care Programs | 1 | 2009 | 347 | 0.290 |
Why?
|
| Cluster Analysis | 3 | 2024 | 96 | 0.290 |
Why?
|
| Medicare | 4 | 2022 | 214 | 0.280 |
Why?
|
| Disease Management | 2 | 2019 | 143 | 0.280 |
Why?
|
| Acute Disease | 3 | 2022 | 144 | 0.270 |
Why?
|
| Length of Stay | 2 | 2018 | 183 | 0.270 |
Why?
|
| Medical Order Entry Systems | 2 | 2016 | 15 | 0.260 |
Why?
|
| Outpatients | 2 | 2019 | 111 | 0.260 |
Why?
|
| Neoplasms | 2 | 2021 | 457 | 0.260 |
Why?
|
| Personal Health Services | 1 | 2005 | 4 | 0.260 |
Why?
|
| Fibrinolytic Agents | 2 | 2016 | 44 | 0.260 |
Why?
|
| Referral and Consultation | 2 | 2024 | 180 | 0.250 |
Why?
|
| Population Surveillance | 4 | 2015 | 271 | 0.250 |
Why?
|
| Gonorrhea | 2 | 2015 | 19 | 0.250 |
Why?
|
| Pediatrics | 2 | 2024 | 166 | 0.240 |
Why?
|
| Health Care Surveys | 5 | 2014 | 247 | 0.240 |
Why?
|
| Meningitis, Bacterial | 1 | 2024 | 1 | 0.240 |
Why?
|
| Intracranial Aneurysm | 1 | 2024 | 4 | 0.240 |
Why?
|
| Emergency Treatment | 2 | 2014 | 8 | 0.230 |
Why?
|
| Patient Selection | 3 | 2020 | 198 | 0.230 |
Why?
|
| Cholesterol, LDL | 2 | 2015 | 125 | 0.230 |
Why?
|
| Hydronephrosis | 1 | 2023 | 2 | 0.220 |
Why?
|
| Ureteral Calculi | 1 | 2023 | 2 | 0.220 |
Why?
|
| Prescription Fees | 1 | 2003 | 4 | 0.220 |
Why?
|
| Organizations | 1 | 2022 | 10 | 0.210 |
Why?
|
| Back Pain | 1 | 2022 | 33 | 0.210 |
Why?
|
| Leadership | 1 | 2022 | 45 | 0.200 |
Why?
|
| Head Injuries, Closed | 1 | 2021 | 1 | 0.200 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2021 | 4 | 0.200 |
Why?
|
| Time Factors | 8 | 2024 | 1136 | 0.200 |
Why?
|
| Appointments and Schedules | 1 | 2021 | 34 | 0.190 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 7 | 0.190 |
Why?
|
| Workload | 1 | 2021 | 30 | 0.190 |
Why?
|
| Incidence | 3 | 2021 | 1314 | 0.190 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2021 | 95 | 0.180 |
Why?
|
| Acute Kidney Injury | 1 | 2021 | 43 | 0.180 |
Why?
|
| Electric Countershock | 2 | 2017 | 16 | 0.180 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2017 | 12 | 0.180 |
Why?
|
| Propensity Score | 1 | 2021 | 94 | 0.180 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 6 | 0.180 |
Why?
|
| Socioeconomic Factors | 4 | 2017 | 673 | 0.180 |
Why?
|
| Transportation | 1 | 2020 | 13 | 0.180 |
Why?
|
| Heart Arrest | 1 | 2020 | 32 | 0.180 |
Why?
|
| Acute Coronary Syndrome | 1 | 2020 | 17 | 0.180 |
Why?
|
| Syncope | 1 | 2020 | 12 | 0.180 |
Why?
|
| Risk Factors | 8 | 2024 | 3449 | 0.180 |
Why?
|
| Occupational Stress | 1 | 2019 | 3 | 0.180 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1173 | 0.170 |
Why?
|
| Self-Management | 1 | 2020 | 30 | 0.170 |
Why?
|
| Erythrocyte Transfusion | 1 | 2019 | 9 | 0.170 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2019 | 20 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 54 | 0.170 |
Why?
|
| Text Messaging | 1 | 2019 | 31 | 0.170 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.170 |
Why?
|
| After-Hours Care | 1 | 2018 | 3 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2020 | 1314 | 0.160 |
Why?
|
| Cancer Survivors | 1 | 2020 | 89 | 0.160 |
Why?
|
| Neisseria gonorrhoeae | 2 | 2015 | 2 | 0.160 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 249 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2017 | 14 | 0.150 |
Why?
|
| Electrocardiography | 3 | 2024 | 44 | 0.150 |
Why?
|
| Prognosis | 4 | 2024 | 624 | 0.150 |
Why?
|
| Australia | 1 | 2017 | 23 | 0.150 |
Why?
|
| Atherosclerosis | 1 | 2018 | 51 | 0.140 |
Why?
|
| Health Status | 3 | 2015 | 328 | 0.140 |
Why?
|
| Comorbidity | 2 | 2017 | 619 | 0.140 |
Why?
|
| Continuity of Patient Care | 2 | 2015 | 112 | 0.140 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 47 | 0.140 |
Why?
|
| Logistic Models | 6 | 2019 | 962 | 0.140 |
Why?
|
| Guideline Adherence | 2 | 2015 | 162 | 0.140 |
Why?
|
| Demography | 1 | 2016 | 108 | 0.140 |
Why?
|
| Costs and Cost Analysis | 2 | 2015 | 89 | 0.130 |
Why?
|
| Patient Preference | 1 | 2016 | 45 | 0.130 |
Why?
|
| Models, Economic | 1 | 2015 | 22 | 0.130 |
Why?
|
| Abdominal Pain | 3 | 2020 | 15 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 182 | 0.130 |
Why?
|
| Prescription Drugs | 1 | 2015 | 33 | 0.130 |
Why?
|
| Quality of Life | 2 | 2018 | 529 | 0.130 |
Why?
|
| Poverty | 2 | 2014 | 182 | 0.130 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 724 | 0.130 |
Why?
|
| Ceftriaxone | 1 | 2015 | 2 | 0.130 |
Why?
|
| Health Information Exchange | 1 | 2014 | 4 | 0.120 |
Why?
|
| Pneumothorax | 1 | 2014 | 2 | 0.120 |
Why?
|
| Thorax | 1 | 2014 | 5 | 0.120 |
Why?
|
| Censuses | 1 | 2014 | 32 | 0.120 |
Why?
|
| Housing | 1 | 2014 | 40 | 0.120 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 526 | 0.120 |
Why?
|
| Hypertension | 1 | 2019 | 524 | 0.120 |
Why?
|
| Blood Coagulation Disorders | 1 | 2014 | 3 | 0.120 |
Why?
|
| Quality Improvement | 2 | 2015 | 207 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 15 | 0.120 |
Why?
|
| Hemorrhage | 1 | 2014 | 63 | 0.110 |
Why?
|
| Patient Care | 1 | 2013 | 36 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2014 | 108 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 656 | 0.110 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2013 | 1 | 0.110 |
Why?
|
| Medicare Part D | 1 | 2013 | 21 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 142 | 0.110 |
Why?
|
| Troponin | 2 | 2024 | 9 | 0.110 |
Why?
|
| Drug Monitoring | 1 | 2012 | 22 | 0.110 |
Why?
|
| Myocardial Revascularization | 2 | 2024 | 12 | 0.110 |
Why?
|
| Hypolipidemic Agents | 1 | 2012 | 44 | 0.100 |
Why?
|
| American Recovery and Reinvestment Act | 1 | 2012 | 1 | 0.100 |
Why?
|
| Consumer Health Information | 1 | 2012 | 14 | 0.100 |
Why?
|
| Certification | 1 | 2011 | 3 | 0.100 |
Why?
|
| Disease Outbreaks | 1 | 2012 | 39 | 0.100 |
Why?
|
| Gastroenteritis | 1 | 2012 | 25 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2012 | 319 | 0.100 |
Why?
|
| Primary Prevention | 1 | 2012 | 79 | 0.100 |
Why?
|
| Cause of Death | 1 | 2012 | 185 | 0.100 |
Why?
|
| Registries | 1 | 2013 | 490 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2023 | 1296 | 0.100 |
Why?
|
| Sex Factors | 3 | 2021 | 661 | 0.090 |
Why?
|
| Models, Organizational | 1 | 2010 | 65 | 0.090 |
Why?
|
| Medically Uninsured | 1 | 2010 | 61 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2010 | 71 | 0.090 |
Why?
|
| Patient Care Management | 1 | 2009 | 32 | 0.080 |
Why?
|
| Decision Making | 2 | 2008 | 204 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 321 | 0.080 |
Why?
|
| ROC Curve | 2 | 2020 | 83 | 0.080 |
Why?
|
| Emergency Medicine | 1 | 2008 | 6 | 0.080 |
Why?
|
| Glasgow Coma Scale | 2 | 2021 | 3 | 0.080 |
Why?
|
| Drug Utilization | 1 | 2008 | 134 | 0.070 |
Why?
|
| Decision Support Techniques | 2 | 2019 | 95 | 0.070 |
Why?
|
| Algorithms | 2 | 2023 | 241 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 630 | 0.070 |
Why?
|
| Prevalence | 2 | 2023 | 911 | 0.070 |
Why?
|
| Educational Status | 3 | 2014 | 205 | 0.070 |
Why?
|
| Computed Tomography Angiography | 1 | 2024 | 4 | 0.060 |
Why?
|
| Clinical Protocols | 2 | 2015 | 45 | 0.060 |
Why?
|
| Headache | 1 | 2024 | 14 | 0.060 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 2 | 0.060 |
Why?
|
| Clinical Decision-Making | 1 | 2023 | 36 | 0.060 |
Why?
|
| Patients | 1 | 2023 | 38 | 0.060 |
Why?
|
| Survival Rate | 2 | 2015 | 269 | 0.060 |
Why?
|
| Biomarkers | 1 | 2024 | 308 | 0.050 |
Why?
|
| Fever | 1 | 2023 | 60 | 0.050 |
Why?
|
| Heart Rate | 1 | 2023 | 40 | 0.050 |
Why?
|
| Drugs, Generic | 1 | 2003 | 5 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2023 | 56 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2015 | 150 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2024 | 872 | 0.050 |
Why?
|
| Drug Prescriptions | 1 | 2003 | 157 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 342 | 0.050 |
Why?
|
| Troponin I | 1 | 2020 | 8 | 0.050 |
Why?
|
| House Calls | 1 | 2020 | 13 | 0.040 |
Why?
|
| Software | 1 | 2019 | 21 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.040 |
Why?
|
| Proxy | 1 | 2019 | 4 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2019 | 47 | 0.040 |
Why?
|
| Nausea | 1 | 2019 | 7 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 22 | 0.040 |
Why?
|
| Vomiting | 1 | 2019 | 12 | 0.040 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2020 | 51 | 0.040 |
Why?
|
| Mortality | 1 | 2020 | 123 | 0.040 |
Why?
|
| Confidentiality | 1 | 2019 | 30 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 61 | 0.040 |
Why?
|
| Migraine Disorders | 1 | 2019 | 16 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2020 | 106 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 133 | 0.040 |
Why?
|
| Medicaid | 1 | 2020 | 211 | 0.040 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 21 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 150 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2015 | 7 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2015 | 23 | 0.030 |
Why?
|
| Cross Infection | 1 | 2015 | 28 | 0.030 |
Why?
|
| Automation | 1 | 2015 | 24 | 0.030 |
Why?
|
| Doxycycline | 1 | 2015 | 1 | 0.030 |
Why?
|
| Cephalosporin Resistance | 1 | 2015 | 1 | 0.030 |
Why?
|
| Azithromycin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Cephalosporins | 1 | 2015 | 8 | 0.030 |
Why?
|
| Documentation | 1 | 2015 | 45 | 0.030 |
Why?
|
| Meaningful Use | 1 | 2014 | 5 | 0.030 |
Why?
|
| Sentinel Surveillance | 1 | 2014 | 14 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2015 | 37 | 0.030 |
Why?
|
| Hospitals, Community | 1 | 2014 | 23 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 119 | 0.030 |
Why?
|
| Ultrasonography, Interventional | 1 | 2014 | 4 | 0.030 |
Why?
|
| Inservice Training | 1 | 2014 | 15 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2014 | 50 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2014 | 51 | 0.030 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 102 | 0.030 |
Why?
|
| Random Allocation | 1 | 2013 | 41 | 0.030 |
Why?
|
| Radiography | 1 | 2013 | 41 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 2012 | 2 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 5 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2012 | 12 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2015 | 162 | 0.030 |
Why?
|
| Physical Examination | 1 | 2012 | 21 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2013 | 244 | 0.030 |
Why?
|
| Education, Medical, Continuing | 1 | 2012 | 31 | 0.030 |
Why?
|
| Community Health Workers | 1 | 2012 | 15 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2012 | 69 | 0.030 |
Why?
|
| Cryptosporidium | 1 | 2012 | 1 | 0.030 |
Why?
|
| Salmonella | 1 | 2012 | 1 | 0.030 |
Why?
|
| Self Report | 1 | 2014 | 256 | 0.030 |
Why?
|
| Serotyping | 1 | 2012 | 5 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 2012 | 4 | 0.030 |
Why?
|
| Antidiarrheals | 1 | 2012 | 2 | 0.030 |
Why?
|
| Economic Recession | 1 | 2012 | 4 | 0.030 |
Why?
|
| Unemployment | 1 | 2012 | 11 | 0.030 |
Why?
|
| Foodborne Diseases | 1 | 2012 | 5 | 0.030 |
Why?
|
| Comprehensive Health Care | 1 | 2012 | 7 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2014 | 256 | 0.030 |
Why?
|
| Financing, Government | 1 | 2012 | 32 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2012 | 253 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2011 | 28 | 0.020 |
Why?
|
| Feces | 1 | 2012 | 88 | 0.020 |
Why?
|
| Risk | 1 | 2012 | 552 | 0.020 |
Why?
|
| Medical Staff | 1 | 2010 | 2 | 0.020 |
Why?
|
| Denmark | 1 | 2010 | 19 | 0.020 |
Why?
|
| Professional Role | 1 | 2010 | 10 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2010 | 47 | 0.020 |
Why?
|
| New York City | 1 | 2010 | 22 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2010 | 20 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2009 | 27 | 0.020 |
Why?
|
| Family Practice | 1 | 2009 | 53 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 399 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2004 | 701 | 0.010 |
Why?
|
| Health Behavior | 1 | 2004 | 374 | 0.010 |
Why?
|